Medical network on March 23 - as the Chinese medicine economy into normal generation, China prescription drug market growth has slowed, but there is still one of the world's most chance of medical market. 2016 prescription drugs in the transnational giants of the top ten, nine have been deep in the Chinese market for years, only, not to enter the Chinese market. And has the world's "who" fix merlot multinational biopharmaceutical company Abbvie (Abbvie), from the point of m Intranet data, the pace of expansion in the Chinese market is still poor, China SEO oz lang admitted in an interview also "examination and approval and the two major challenges facing the health care is its".
1, the big three years sales more than $170 billion
Foreign drug companies from 2015 to 2016 the total sales revenue of the global top 10 (unit: us $)
At present, the global pharmaceutical giant published annual reports in 2016, top 10 pharmaceutical companies also is emerging. Johnson & Johnson group was ranked the first, with $71.89 billion year-on-year growth of 3%, Pfizer, bayer, roche, in turn, in the next, sales were higher than $50 billion. Growth rate, growth of 8%, Pfizer j&j grew 3%, bayer and roche are increased by 4%. Johnson & Johnson, Pfizer, bayer is a global leading enterprise in medicine still three total sales revenue of more than $170 billion.
It is worth mentioning that abbvie in 2016 sales revenue of 25.638 billion yuan, ranked tenth, but the company's wood single sheet is tasted, resistance (merlot) with annual sales of $16.078 billion for "who" in the world.
2, the $16 billion global "who" tempered
Nearly five years, wood single resistance (merlot) global sales list (unit: us $)
Abbvie come from abbott split professional prescription pharmaceutical enterprise, Ada wood sheet resistance is developed by abbvie, on December 31, 2002, American FDA approval, on September 8, 2003 won European approval of EMA, on April 16, 2008 PMDA, Japan has approved, on February 26, 2010 listed on the CFDA granted, and by the abbvie sales in the United States, Europe, Japan and China market, commodity called Humira (merlot).
As one of the world's most popular anti-inflammatory drugs, merlot since listing has won approval of more than 90 countries around the world, 14 worldwide approved indications, market 10 indication approved in the United States, the world more than 980000 patients undergoing repairs merlot treatment.
3, "who" the world's bestselling, tepid domestic sales
However, behind the aura, repairing the merlot sales in the Chinese market has been tepid. According to m, according to data from the network in China's urban public hospitals, public hospitals at the county level, community center of cities and towns and townships (hereinafter referred to as "China's public medical institutions") chemical medicine pattern china-arab da wood sheet resistance injection in 2015 sales for 037 million yuan only.
Chinese public medical institutions chemical medicine pattern china-arab da wood single injection annual sales resistance (unit: ten thousand yuan)
That abbvie China general manager Mr Lang said, "take merlot in most countries in the region have been given access to healthcare, autoimmune disease and rheumatoid disease areas in China is still not to enter the national health insurance directory list, so we face the main still is given priority to with own patients."
According to understand, merlot is aimed at represented by rheumatoid arthritis autoimmune disease, need medication for a long time, would have to take it once every 1 ~ 2 weeks, the price of each up to more than 7000 yuan, which makes the domestic most of the patients.
conclusion
In recent years, merlot in global continuous in billions of dollars in sales, the position of "who" can continue to retain remains to be seen. Reports have pointed out that fix merlot similar biological medicine is gradually approaching, in September 2016, amgen has obtained the FDA to build a merlot similar drug approval in advance. The personage inside course of study says, merlot wanted in the Chinese market, unless the product price reductions or into the medical insurance directory, or in China to achieve its good performance has great difficulty in foreign countries. |
